This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Enzo Biochem Reports Fourth Quarter And Fiscal Year Results

About Enzo Biochem

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and therapeutics through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products systems and services that meet the ever-changing and rapidly growing needs of health care both today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.

Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses are dependent on a number of factors outside of the control of the company including, inter alia, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigations, and general business conditions. See Risk Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2013. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.
(in thousands, except per share data)
Three months ended Fiscal Year ended

Selected operations data:
July 31, July 31,
(unaudited) (unaudited)




Clinical laboratory services $14,008 $15,851 $55,889 $59,403
Product revenues $7,951 $8,903 $32,526 $37,722
Royalty and license fee income $1,310   $1,654   $5,292     $5,958  
Total revenues $23,269   $26,408   $93,707   $103,083  
Gross profit $9,446   $11,673   $38,872   $47,110  
Gross profit % 41 % 44 % 41 % 46 %
Loss before income taxes ($3,532 ) ($29,074 ) ($18,949 ) ($40,921 )
Benefit for income taxes (A) 430 1,931 712 1,652
Net loss ($3,102 ) ($27,143 ) ($18,237 ) ($39,269 )
Basic and diluted loss per share ($0.08 ) ($0.69 ) ($0.46 ) ($1.01 )
Weighted average shares outstanding - basic and diluted 40,284   39,162   39,607     38,798  

Reconciliation of GAAP Net Loss to EBITDA, as adjusted:
Net loss ($3,102 ) ($27,143 ) ($18,237 ) ($39,269 )
Add-back (deduct):
Depreciation and amortization 1,108 1,191 4,605 4,477
Interest expense (income) 29 (27 ) 54 (21 )
(Benefit) for income taxes (430 ) (1,931 ) (712 ) (1,652 )
EBITDA (B) ($2,395 ) ($27,910 ) ($14,290 ) ($36,465 )
Non cash impairment charges and incremental severance - C   $24,840     $24,840  
EBITDA (B), as adjusted ($2,395 ) ($3,070 ) ($14,290 ) ($11,625 )

A- All periods reflect effective tax rates below the statutory rate due to inability to recognize future tax benefits.
B- EBITDA is a non-GAAP measure, as described in the attached press release

C- EBITDA, adjusted for non-cash impairment charges relating to goodwill and intangibles of $24.5 million and incremental one-time severance costs of $0.3 million.


Selected balance sheet data:
July 31, 2013 July 31, 2012
Cash and cash equivalents $9,007 $15,076
Working capital $8,704 $21,412
Stockholders' equity $34,132 $49,101
Total assets $58,958 $69,123

4 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.64 -0.11%
FB $118.57 0.84%
GOOG $698.21 0.75%
TSLA $241.80 0.43%
YHOO $36.53 -0.19%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs